Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications

Fei Yuan Hsiao, Yu Hsuan Yen, Chun-Nin Lee, Weng Foung Huang, Hsiang Yin Chen

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Antituberculosis therapy frequently causes hepatotoxicity. The study is to evaluate the appropriateness of liver function monitoring during antituberculosis therapy. Two hundred forty five patients treated with antituberculosis agents were included. Abnormal baseline liver function (LFT) was the most significant risk factor for developing hepatotoxicity during the therapy (adjusted OR 23.48; 95%CI: 9.74-56.61). However, the baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were only checked in 76.2% and 75.4% subjects in the hepatotoxic group; and even lower to 58.5% and 57.8% for the non-hepatotoxic group. Although smoking, severe drinking, age, gender and concurrent diseases were significant risk factors, the logistic regression showed that only abnormal baseline LFT (adjusted OR 2.21; 95%CI: 1.22-4.02) and age (adjusted OR 1.02; 95%CI: 1.01-1.04) were determinants of patients receiving follow-up liver function tests (LFTs). Effective strategies to improve the monitoring of liver function should be established to ensure patient safety.

Original languageEnglish
Pages (from-to)107-114
Number of pages8
JournalTaiwan Pharmaceutical Journal
Issue number4
Publication statusPublished - Dec 2009


  • Antituberculosis medications
  • Hepatotoxicity
  • Liver function tests

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications'. Together they form a unique fingerprint.

Cite this